scholarly journals Effect of Montmorency tart cherry juice on cognitive performance in older adults: a randomized controlled trial

2019 ◽  
Vol 10 (7) ◽  
pp. 4423-4431 ◽  
Author(s):  
Sheau C. Chai ◽  
Jessica Jerusik ◽  
Kristina Davis ◽  
Regina S. Wright ◽  
Zugui Zhang
Keyword(s):  
Blood Pressure ◽  
Older Adults ◽  
Randomized Controlled Trial ◽  
Cognitive Abilities ◽  
Controlled Trial ◽  
Lower Blood Pressure ◽  
Tart Cherry ◽  
Randomized Controlled ◽  
Lower Blood ◽  
Cherry Juice

Daily tart cherry juice consumption may improve cognitive abilities. This may be through anti-oxidative and anti-inflammatory properties of tart cherry and its ability to lower blood pressure.

Comment on “Effect of Montmorency tart cherry juice on cognitive performance in older adults: a randomized controlled trial” by S. C. Chai, J. Jerusik, K. Davis, R. S. Wright and Z. Zhang, Food Funct., 2019, 10, 4423–4431

2020 ◽  
Vol 11 (3) ◽  
pp. 2763-2763
Author(s):  
Thomas F. Heston
Keyword(s):  
Older Adults ◽  
Randomized Controlled Trial ◽  
Cognitive Function ◽  
Cognitive Performance ◽  
Controlled Trial ◽  
Tart Cherry ◽  
Old People ◽  
Randomized Controlled ◽  
Cherry Juice ◽  
Normal Cognitive Function

The article looking at the effect of Montmorency tart cherry juice supplementation on 50 to 80 years old people with normal cognitive function concluded that supplementation may improve cognitive functioning.

CareKnowDo – A Multichannel Digital Support Program for People With Chronic Kidney Disease: A Feasibility Randomized Controlled Trial (Preprint)

2021 ◽  
Author(s):  
Jonathan David Reston ◽  
Fergus Caskey ◽  
Barnaby Hole ◽  
Udaya Udayaraj ◽  
John Weinman
Keyword(s):  
Blood Pressure ◽  
Randomized Controlled Trial ◽  
Kidney Disease ◽  
Controlled Trial ◽  
Support Program ◽  
Self Management ◽  
Lower Blood Pressure ◽  
Randomized Controlled ◽  
Lower Blood

BACKGROUND Chronic Kidney Disease (CKD) is a common, progressive condition. Lifestyle changes and antihypertensive medication can slow progression to end stage kidney disease, requiring renal replacement therapy. However, adherence to these recommendations is often low. OBJECTIVE The aim of CareKnowDo was to assess the feasibility of rolling out a digital self-management support and adherence program integrated with a patient-facing electronic health record, Patient View (PV). METHODS A two arm, parallel, individual-level pragmatic feasibility pilot randomized controlled trial (RCT), running in two NHS sites in the UK. Sixty-one patients with CKD were randomized 1:1 into two groups and provided with either a new tailored, digital support program (CareKnowDo, n = 31) integrated with PV, or standard care (PV alone, n = 30). Quantitative measures included clinical and psychosocial measures. The primary outcomes were feasibility based; recruitment rate, drop-out, and exploration of associations. RESULTS Out of 1,392 patients screened in local kidney clinics, 269 met the basic inclusion criteria, the first eligible 61 of whom were recruited to participate in the study. Twenty-three patients (37.7%) completed the final 6-month follow-up survey. Reasons for attrition are explored. Higher belief in the ability of treatment to control CKD was associated with lower blood pressure at baseline (r = .52, P = 0.005), and higher perceived understanding of CKD at baseline was associated with lower blood pressure at follow-up (r = 0.66, P < .001). Beliefs about medicines at baseline were associated with blood pressure at baseline, but not at follow-up. This was true for both concerns about medicines (r = .A digital support program to enhance support for patients with CKD was piloted in two NHS sites, and found to be feasible and acceptable. However, to maximize the effectiveness of the intervention (and of future trials), consideration should be given to the target audience most likely to benefit, as well as how to help them access the program as quickly and easily as possible.58, P = .001) and perceived necessity of medicines (r = .42, P = .03). CONCLUSIONS A digital support program to enhance support for patients with CKD was piloted in two NHS sites, and found to be feasible and acceptable. However, to maximize the effectiveness of the intervention (and of future trials), consideration should be given to the target audience most likely to benefit, as well as how to help them access the program as quickly and easily as possible. CLINICALTRIAL Kidney disease, chronic; blood pressure; randomized controlled trial; telemedicine; mhealth; self-management; guideline adherence; medication adherence; illness beliefs; treatment beliefs; health psychology; preventative medicine; qualitative research

Effects of exercise training on home blood pressure values in older adults: a randomized controlled trial

2001 ◽  
Vol 19 (6) ◽  
pp. 1045-1052 ◽  
Author(s):  
Takayoshi Ohkubo ◽  
Atsushi Hozawa ◽  
Ryoichi Nagatomi ◽  
Kazuki Fujita ◽  
Catherine Sauvaget ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Older Adults ◽  
Randomized Controlled Trial ◽  
Exercise Training ◽  
Controlled Trial ◽  
Home Blood Pressure ◽  
Randomized Controlled

scholarly journals Promoting Physical Activity in Older Adults With Knee Osteoarthritis and Hypertension: A Randomized Controlled Trial

2020 ◽  
pp. 1-12 ◽  
Author(s):  
Elizabeth A. Schlenk ◽  
G. Kelley Fitzgerald ◽  
Joan C. Rogers ◽  
C. Kent Kwoh ◽  
Susan M. Sereika
Keyword(s):  
Physical Activity ◽  
Blood Pressure ◽  
Older Adults ◽  
Randomized Controlled Trial ◽  
Lower Extremity ◽  
Self Efficacy ◽  
Controlled Trial ◽  
Attention Control ◽  
Outcome Expectancy ◽  
Randomized Controlled

A 6-month self-efficacy intervention was compared with attention-control intervention on physical activity, clinical outcomes, and mediators immediate postintervention and 6-month postintervention in 182 older adults with knee osteoarthritis and hypertension using a randomized controlled trial design. The intervention group received six weekly individual physical therapy sessions for lower-extremity exercise and fitness walking and nine biweekly nurse telephone counseling sessions. The attention-control group received six weekly and nine biweekly nurse telephone sessions on health topics. Lower-extremity exercise was assessed by e-diary; fitness walking was assessed by accelerometer and e-diary; blood pressure was assessed by automated monitor; function was assessed by performance-based tests and questionnaires; and pain, self-efficacy, and outcome expectancy were assessed by questionnaires. Self-reported lower-extremity exercise and fitness walking, function, pain, self-efficacy, and outcome expectancy showed significant group or group by time effects favoring intervention. The intervention did not improve physical activity by accelerometer and blood pressure. Mean minutes of fitness walking fell short of the 150 min/week goal.

scholarly journals Effects of Montmorency Tart Cherry and Blueberry Juice on Cardiometabolic Outcomes in Healthy Individuals: Protocol for a 3-Arm Placebo Randomized Controlled Trial

2021 ◽  
Vol 18 (18) ◽  
pp. 9759
Author(s):  
Jonathan Sinclair ◽  
Gareth Shadwell ◽  
Stephanie Dillon ◽  
Robert Allan ◽  
Bobbie Butters ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Secondary Outcome ◽  
Cardiometabolic Disease ◽  
Primary Study ◽  
Tart Cherry ◽  
Randomized Controlled ◽  
Blueberry Juice ◽  
Natural Treatment

Cardiometabolic disease is recognized as the predominant cause of global mortality and healthcare expenditure. Whilst pharmaceutical interventions are effective in the short term, their long-term efficacy remain equivocal and their associated side-effects are concerning. Owing to their high levels of anthocyanins, Montmorency tart cherries and blueberries have been cited as potentially important natural treatment/preventative modalities for cardiometabolic disease. This study proposed a randomized controlled trial, aims to test the effects of consumption of Montmorency tart cherry and blueberry juice on cardiometabolic outcomes compared to placebo. This 20-day, parallel, single-blind, randomized, placebo-controlled trial will recruit 45 individuals, who will be assigned to receive 60 mL per day of either Montmorency tart cherry juice, blueberry juice or a cherry/blueberry flavoured placebo. The primary study outcome is the between-group difference in systolic blood pressure from baseline to post-intervention. Secondary outcome measures will be between-group differences in anthropometric, energy expenditure and substrate oxidation (during rest and physical activity), haematological, blood pressure/resting heart rate, psychological wellbeing and sleep efficacy indices. Statistical analysis will be conducted on an intention-to-treat basis. This study has been granted ethical approval by the University of Central Lancashire, Health Research Ethics Committee (ref: HEALTH 0016) and formally registered as a trial. Dissemination of the study findings from this investigation will be through publication in a leading peer-reviewed journal.

Sign in / Sign up

Export Citation Format

Share Document